BioSpectrum Asia

EditForce & Mitsubishi ink gene therapy deal for ¥20 B


Japan-based EditForce has entered into a license agreement with Mitsubishi

Tanabe Pharma Corporatio­n (MTPC) to research, develop and commercial­ize potential gene therapy products for a specific target disease in the field of CNS by utilising EditForce’s proprietar­y PPR protein platform technology. In this alliance, MTPC and EditForce aim to create potential novel pharmaceut­icals for the specific CNS disease by utilizing the drug R&D know-how and global business experience of MTPC and the novel biotechnol­ogy of EditForce. MTPC will acquire the exclusive right to conduct the selection of drug candidate molecules, preclinica­l and clinical developmen­t, manufactur­ing, and commercial­ization worldwide. Under the terms of the Agreement, EditForce will receive an upfront payment and milestone payments amounting to over 20 billion yen depending on the developmen­t stage and commercial­ization progress, and royalties based on worldwide sales after the launch.

Newspapers in English

Newspapers from India